What is the average dose of Wegovy for weight loss?

What does the full Wegovy titration schedule look like?

The UK licensed schedule for Wegovy injection starts at 0.25 mg once a week. After roughly four weeks, if tolerated, the prescriber moves you to 0.5 mg, then 1.0 mg, then 1.7 mg, and finally 2.4 mg, the standard maintenance dose. That's a minimum of around 16 weeks to reach maintenance, though many people take longer if nausea or other gastrointestinal effects are noticeable after a step up. You can read the full technical dosing framework in the NHS semaglutide medicines guide.

Since January 2026, a further step to 7.2 mg is also licensed in the UK for adults with a BMI of 30 or above who need additional effect at 2.4 mg. The MHRA approved a dedicated single-dose 7.2 mg pen in April 2026, one pre-set injection per week, auto-dosing, with no manual dialling required. Trials at this higher dose reported an average weight reduction of around 20.7% over 72 weeks, bringing results closer to those seen with tirzepatide at the top of its own range. Whether 7.2 mg is the right dose for any individual is a conversation between the patient and their prescriber; availability of specific pen formats is confirmed at consultation rather than assumed.

More detail on how each strength fits the broader treatment picture is covered on our Wegovy dosage overview.

Why does the titration go so slowly, can you speed it up?

The step-up schedule exists for a straightforward reason: semaglutide slows how quickly the stomach empties, and starting at a therapeutic dose immediately would cause severe nausea for most people. The four-week periods at each level give the gut time to adapt. It's not unusual for patients to describe the first week after a step up as the roughest, followed by a gradual settling.

Rushing the schedule carries real downsides. More intense GI symptoms (nausea, vomiting, diarrhoea) are the most common consequence, and in some cases they're severe enough that people stop treatment early, losing any benefit they'd built. Slowing down or repeating a dose level is a legitimate clinical choice, not a setback. Your prescriber decides timing based on your reported tolerance; self-adjusting is not appropriate for a prescription medicine.

Some people also find that a lower dose than 2.4 mg produces enough effect and that stepping further isn't necessary or wanted. The weight loss seen even at the earlier doses is meaningful for some individuals, and the prescriber weighs that against the push toward maximum dose. This is precisely why clinical review before each repeat matters.

Who reaches the 2.4 mg or 7.2 mg maintenance dose, and who doesn't?

In clinical trials, the majority of participants without intolerable side effects did reach the 2.4 mg maintenance dose. If you're curious about what the average dose of Wegovy looks like for weight loss, the picture from trial data is that most people who tolerate the titration well do reach the full maintenance level. That average carries the usual caveats: some people lost considerably more, some less, and results depend heavily on diet, activity and how well the dose was tolerated throughout.

The 7.2 mg dose is newer and not yet the default expectation. It suits those who've tolerated 2.4 mg well but whose prescriber judges that a further therapeutic push is clinically warranted. It's also worth being clear that Wegovy is a prescription-only medicine, NICE's appraisal of semaglutide for weight management (TA875) sets out the eligibility criteria that inform both NHS and private prescribing decisions, including the six-month review of response at maintenance dose.

A practical note on storage: the pen lives in the fridge between doses, so most people slot it into a designated spot in the fridge door alongside other regulars. It's a small habit that helps avoid the accidental room-temperature exposure that can compromise the medicine, the Patient Information Leaflet gives the exact time window for safe use outside the fridge, and that's the document to follow, not a generic online estimate.

Does the dose you end up on affect how much weight you lose?

Generally, yes, higher maintenance doses are associated with greater average weight reduction in the trial data. But the relationship isn't mechanical. Factors including baseline weight, diet quality, physical activity, adherence to the titration schedule, and individual metabolic response all shape outcomes. The average figures from trials are population summaries; your prescriber is interested in your trajectory, not the average.

If you're considering Wegovy and want to understand which Wegovy dose you might realistically work toward, that's a conversation that starts with a clinical assessment. The full Wegovy treatment overview covers eligibility, the access route through a GPhC-registered pharmacy, and what to expect from the process. For those weighing up costs alongside dose, the Wegovy cost breakdown sets out what a transparent private prescription actually includes. Wegovy is available only on prescription following clinical assessment; a prescriber reviews your suitability before any treatment begins. Check your eligibility with our prescribers if you'd like to take that step.